Idiopathic Central Precocious Puberty(ICPP): Efficacy of GnRH Analogues (GnRHa)Treatment in 81 Girls Assisted in a SinglePediatric Endocrine Center

ARCARI, ANDREA; ESCOBAR, MARÍA EUGENIA; BALLERINI, MARÍA GABRIELA; FREIRE, ANALÍA; ROPELATO, MARÍA GABRIELA; BERGADÁ, IGNACIO; GRYNGARTEN, MIRTA

Montevideo

Congreso; XXIII Annual Meeting of the Paediatrics Endocrinology Latinoamerican Society; 2012

XXIII Annual Meeting of the Paediatrics Endocrinology Latinoamerican Society

ICPP is characterized by precocious sexual development and accelerated bone maturation with consequent impairment of adult height (AH). GnRHa is the treatment of choice for ICPP. Objective: To assess AH and to determine factors influencing AH in girls with ICPP treated with GnRHa. Patients and Methods: 81 girls with ICPP treated with GnRHa who had reached AH were included. Clinical features, target height (TH), bone age (BA) and predicted adult height (PAH) by G&P were assessed. Univariate and multivariate analyses of the factors potentially associated with AH were performed (Infostat 2008). Data are shown as mean ± SE. Results: At start of treatment Chronological age (CA) was 7.53±0.17(0.8–7.9) years. Bone age (BA) was 9.78±0.21 years and BA-CA was 2.3±0.11years. Initial height was 131.8±1.29 cm and PAH was 154±0.74 cm. Patients were treated for 2.7±0.2 years. All patients showed clinical and hormonal parameters of adequate therapeutic response. At end of treatment CA was 10.32±0.05 years, BA was 11.9±0.07, BA-CA was 1.64±0.09, height was 147.7±0.70, PHA was 159.9±0.76 cm. AH was 160.47±0.72 cm no different to TH (160.02±0.62 cm). AH-PAH at the start was 6.06±0.63 cm. Data of univariate analyses showed no correlation between BA and CA at start of treatment with AH. Multiple linear regression analysis showed a significant positive association of AH with height at end of treatment, TH and % of TH achieved at end of treatment (p=0.0012) Interval between CA at onset of puberty and CA at start of therapy showed significant and negative association with AH. (p<0.05) Postreatment linear growth showed a significant negative association with BA at end and significant positive association with the interval between CA at end of treatment and age at menarche (p<0.0001).To assess AH and to determine factors influencing AH in girls with ICPP treated with GnRHa. Patients and Methods: 81 girls with ICPP treated with GnRHa who had reached AH were included. Clinical features, target height (TH), bone age (BA) and predicted adult height (PAH) by G&P were assessed. Univariate and multivariate analyses of the factors potentially associated with AH were performed (Infostat 2008). Data are shown as mean ± SE. Results: At start of treatment Chronological age (CA) was 7.53±0.17(0.8–7.9) years. Bone age (BA) was 9.78±0.21 years and BA-CA was 2.3±0.11years. Initial height was 131.8±1.29 cm and PAH was 154±0.74 cm. Patients were treated for 2.7±0.2 years. All patients showed clinical and hormonal parameters of adequate therapeutic response. At end of treatment CA was 10.32±0.05 years, BA was 11.9±0.07, BA-CA was 1.64±0.09, height was 147.7±0.70, PHA was 159.9±0.76 cm. AH was 160.47±0.72 cm no different to TH (160.02±0.62 cm). AH-PAH at the start was 6.06±0.63 cm. Data of univariate analyses showed no correlation between BA and CA at start of treatment with AH. Multiple linear regression analysis showed a significant positive association of AH with height at end of treatment, TH and % of TH achieved at end of treatment (p=0.0012) Interval between CA at onset of puberty and CA at start of therapy showed significant and negative association with AH. (p<0.05) Postreatment linear growth showed a significant negative association with BA at end and significant positive association with the interval between CA at end of treatment and age at menarche (p<0.0001).Patients and Methods: 81 girls with ICPP treated with GnRHa who had reached AH were included. Clinical features, target height (TH), bone age (BA) and predicted adult height (PAH) by G&P were assessed. Univariate and multivariate analyses of the factors potentially associated with AH were performed (Infostat 2008). Data are shown as mean ± SE. Results: At start of treatment Chronological age (CA) was 7.53±0.17(0.8–7.9) years. Bone age (BA) was 9.78±0.21 years and BA-CA was 2.3±0.11years. Initial height was 131.8±1.29 cm and PAH was 154±0.74 cm. Patients were treated for 2.7±0.2 years. All patients showed clinical and hormonal parameters of adequate therapeutic response. At end of treatment CA was 10.32±0.05 years, BA was 11.9±0.07, BA-CA was 1.64±0.09, height was 147.7±0.70, PHA was 159.9±0.76 cm. AH was 160.47±0.72 cm no different to TH (160.02±0.62 cm). AH-PAH at the start was 6.06±0.63 cm. Data of univariate analyses showed no correlation between BA and CA at start of treatment with AH. Multiple linear regression analysis showed a significant positive association of AH with height at end of treatment, TH and % of TH achieved at end of treatment (p=0.0012) Interval between CA at onset of puberty and CA at start of therapy showed significant and negative association with AH. (p<0.05) Postreatment linear growth showed a significant negative association with BA at end and significant positive association with the interval between CA at end of treatment and age at menarche (p<0.0001).81 girls with ICPP treated with GnRHa who had reached AH were included. Clinical features, target height (TH), bone age (BA) and predicted adult height (PAH) by G&P were assessed. Univariate and multivariate analyses of the factors potentially associated with AH were performed (Infostat 2008). Data are shown as mean ± SE. Results: At start of treatment Chronological age (CA) was 7.53±0.17(0.8–7.9) years. Bone age (BA) was 9.78±0.21 years and BA-CA was 2.3±0.11years. Initial height was 131.8±1.29 cm and PAH was 154±0.74 cm. Patients were treated for 2.7±0.2 years. All patients showed clinical and hormonal parameters of adequate therapeutic response. At end of treatment CA was 10.32±0.05 years, BA was 11.9±0.07, BA-CA was 1.64±0.09, height was 147.7±0.70, PHA was 159.9±0.76 cm. AH was 160.47±0.72 cm no different to TH (160.02±0.62 cm). AH-PAH at the start was 6.06±0.63 cm. Data of univariate analyses showed no correlation between BA and CA at start of treatment with AH. Multiple linear regression analysis showed a significant positive association of AH with height at end of treatment, TH and % of TH achieved at end of treatment (p=0.0012) Interval between CA at onset of puberty and CA at start of therapy showed significant and negative association with AH. (p<0.05) Postreatment linear growth showed a significant negative association with BA at end and significant positive association with the interval between CA at end of treatment and age at menarche (p<0.0001).Results: At start of treatment Chronological age (CA) was 7.53±0.17(0.8–7.9) years. Bone age (BA) was 9.78±0.21 years and BA-CA was 2.3±0.11years. Initial height was 131.8±1.29 cm and PAH was 154±0.74 cm. Patients were treated for 2.7±0.2 years. All patients showed clinical and hormonal parameters of adequate therapeutic response. At end of treatment CA was 10.32±0.05 years, BA was 11.9±0.07, BA-CA was 1.64±0.09, height was 147.7±0.70, PHA was 159.9±0.76 cm. AH was 160.47±0.72 cm no different to TH (160.02±0.62 cm). AH-PAH at the start was 6.06±0.63 cm. Data of univariate analyses showed no correlation between BA and CA at start of treatment with AH. Multiple linear regression analysis showed a significant positive association of AH with height at end of treatment, TH and % of TH achieved at end of treatment (p=0.0012) Interval between CA at onset of puberty and CA at start of therapy showed significant and negative association with AH. (p<0.05) Postreatment linear growth showed a significant negative association with BA at end and significant positive association with the interval between CA at end of treatment and age at menarche (p<0.0001). Conclusion: Treatment with a GnRH in ICPP girls showed to be effective to reach a normal AH according to TH, independently of CA at start of treatment.Treatment with a GnRH in ICPP girls showed to be effective to reach a normal AH according to TH, independently of CA at start of treatment.